EFFECT OF CYP2B6 POLYMORPHISM ON PROPOFOL IN PATIENTS UNDERGOING ABDOMINAL HYSTERECTOMY

Abstract

Understanding why individuals respond differently to drug therapy is one of the most intriguing questions in modern medicine and pharmacology. The main premise is that individual differences in genetic variables in genes encoding metabolic enzymes, molecular transporters and propofol molecular binding sites are implicated in the sensitivity to the effects of propofol, a commonly used intravenous anesthetic. The goal of this research was to see how polymorphisms in the cytochrome P450 2B6 isozyme CYP2B6 gene impacted the propofol therapeutic outcomes in patients subjected to abdominal hysterectomy. This study included ninety patients ranging in age from 29 to 74 years old and from various ethnic backgrounds. TaqMan SNP genotyping analysis on Stratagene MxPro 3005P real-time polymerase chain reaction was used to determine the presence of polymorphisms (qPCR). The genetic variations were distributed inside the Hardy-Weinberg equilibrium. The allelic frequencies of polymorphic variations and genotype distributions across adult and elderly patients, as well as patients of different ethnicities, were not significantly different (p>0.05). According to our findings, the CYP2B6 gene variations did not cause any statistically significant effects on the analyzed clinical parameters i.e., doses for induction in anesthesia, additional doses, induction time and awakening time after anesthesia and adverse effects of propofol.